A report released today by Canaccord about Alere (NYSE:ALR) lowers the target price to $53.00
- Updated: September 28, 2016
Boasting a price of $43.20, Alere (NYSE:ALR) traded -0.19% lower on the day. With the last close up 0.63% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time. The company has recorded a 50-day moving average of $41.36 and a 200-day average of $42.85. Volume of trade was down over the average, with 98,513 shares of ALR changing hands under the typical 1,116,490
Canaccord dropped the price target of Alere (NYSE:ALR) to $53.00 reporting a possible upside of 0.23%.
Recent Performance Chart
Alere has with a 52 week low of $31.47 and a 52 week high of $54.13 and has a market capitalization of $0.
In addition to Canaccord reporting its stock price target, a total of 6 firms have reported on the stock. The consensus target price is $54.00 with zero brokerages rating the stock a strong buy, zero analysts rating the company a buy, 7 brokers rating the company a hold, zero firms rating the stock a underperform, and finally zero analysts rating the company a sell.
More About Alere (NYSE:ALR)
Alere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its joint venture with The Procter & Gamble Company (P&G). The Company's professional diagnostic solutions allow patients and their healthcare providers to work together to manage patients' conditions over the continuum of care, from the hospital to home. The Company offers lines of drugs-of-abuse tests, reagent systems and laboratory testing options.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.